Abbreviation · Medical
ROGD
Rapid Onset Gender Dysphoria — gender dysphoria that develops rapidly.
3 min read · updated May 2026
ROGD is a term introduced by researcher Lisa Littman (Brown University) in a 2018 PLOS ONE publication. The term describes a pattern reported by parents: teenagers—predominantly girls (see TIF, FTM, TGM)—who suddenly and without a history of gender dysphoria identify as trans, often in clusters within groups of friends or after intensive use of social media.
For a detailed description of the research and the controversy, see the ROGD page.
Critical analysis
ROGD is one of the most contested terms in the entire debate. Activists dismiss it as “pseudoscience”—under pressure from protests, PLOS ONE was forced to publish a correction. At the same time, the patterns Littman described are observed in virtually every Western country: an explosive increase in transition requests among teenage girls, often in clusters. The Cass Review does not reject ROGD as a hypothesis, but points out that the cause of this trend was insufficiently investigated before clinical care (in GIDS and similar clinics) was rolled out. See also social pressure.
Related
Political function of the acronym
An abbreviation like ROGD is not a linguistic invention but a political instrument. Those who use the abbreviation simultaneously signal their acceptance of the associated ideological framework: identity takes precedence over biology, self-declaration over diagnosis, language over reality. Those who refuse to go along with it are accused of being outdated or hateful.
Resistance to this pressure does not come solely from conservative quarters. Lesbian organizations, sports associations, women’s rights groups, and clinicians are voicing opposition to the shifting of category boundaries. The acronym itself is often defended on the grounds of inclusion, but in practice it forces the abandonment of categories that actually serve a protective function—for women, for lesbians, for children.
Medical Context and the Evidence
The medical side of the debate has completely shifted in just a few years. The Cass Review (2024) found that the evidence base for puberty blockers and cross-sex hormones in minors is weak. Based on this, NHS England ceased routine prescribing. SBU (Sweden, 2022), COHERE (Finland, 2020), UKOM (Norway, 2023), and NICE (UK, 2020) reached the same conclusion.
In communications from organizations that embrace ROGD and related terms, these reevaluations are almost always absent. The image of settled science is maintained by remaining silent about the Cass Review and the Scandinavian shift. The WPATH Files (2024) revealed that even among WPATH clinicians, there is uncertainty regarding informed consent for minors.
Implications for the public debate
Expanding acronyms is not without cost. Every new letter comes with a claim to recognition in legislation, education, and healthcare. Without evidence for the underlying category, policy is pursued as if the evidence were there. Those who ask questions receive no substantive answer but moral condemnation.
Language drives policy. Those who accept the acronym implicitly accept the claim that all identities it encompasses are equal and scientifically grounded. That is a political claim, not a linguistic one. Criticism of an acronym is not criticism of individuals—it is criticism of a framework that is increasingly being placed beyond the reach of debate.
International Reconsideration
In recent years, various national health authorities have distanced themselves from the gender-affirming model for minors. The common denominator: evidence of lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of clinical trials.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital discontinued the use of puberty blockers and hormones for minors outside of clinical trials. Reason: lack of evidence for effectiveness and safety.
NICE — United Kingdom (2020). Two NICE evidence reviews (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised its protocol: psychotherapy as first-line treatment, medical transition for minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified transgender care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians acknowledge that informed consent for minors is problematic and that serious side effects (bone density, fertility, cognitive development) are not adequately explained.